BofA raised the firm’s price target on Stevanato Group (STVN) to $26 from $24 and keeps a Buy rating on the shares. The Life Sciences Tools sector underperformed again in FY24 as Pharma and Biotech customers reined in spending after overspending during the pandemic and China remained “very subdued,” the analyst tells investors. Entering 2025, “the setup is almost identical, so there is a healthy dose of skepticism among investors who have been burned over the past year,” says the firm, which adds that thinks “there are finally some encouraging signs on the horizon.” In conjunction with its year ahead preview for the group, the firm adjusted a number of price targets.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STVN:
- Wolfe starts Stevanato with Outperform on return to growth
- Stevanato Group initiated with an Outperform at Wolfe Research
- Stevanato Group assumed with an Equal Weight at Morgan Stanley
- Stevanato Group Sees Revenue Rise Amid Engineering Challenges
- Stevanato Group price target raised to $24 from $23 at UBS